| Patent application number | Description | Published |
|---|
| 20090163423 | Exendins and Exendin Agonist Analogs to Regulate Gastrointestinal Motility - Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents. | 06-25-2009 |
| 20100130426 | COMPOSITIONS CONTAINING SATIOGENS AND METHODS OF USE - Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases. | 05-27-2010 |
| 20100130472 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES - Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes. | 05-27-2010 |
| 20110034377 | Exendin and Exendin Agonists for Eating Disorders - Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 02-10-2011 |
| 20110152204 | Treatment of Obesity or Diabetes with Bile Acid Sequestrants - Provided herein are methods of treating obesity and diabetes with labile bile acid sequestrants. An effective amount of a labile bile acid sequestrant may be orally administered to an obese or diabetic individual. A labile bile acid sequestrant provided herein may have a low affinity in the colon or rectum of a human for at least one bile acid or bile acid mimic that stimulates L-cells. A labile bile acid sequestrant may be a non-systemic labile bile acid sequestrant. | 06-23-2011 |
| 20110294767 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS - Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions. | 12-01-2011 |
| 20110306549 | GLP-1 RECEPTOR AGONISTS TO TREAT PANCREATITIS - The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide. | 12-15-2011 |
